Fifty years of restricted research may be coming to an end. Reports that President Trump plans to direct cannabis rescheduling would finally open federally-funded clinical trials for cannabinoid therapeutics, and force the industry to answer questions it’s long avoided. Pharma companies like Jazz (Epidiolex) and AbbVie already have cannabinoid programs. This could accelerate M&A or…